ALLO vs. ALEC, PROK, VYGR, VALN, CCCC, EDIT, TSHA, ADPT, HUMA, and ITOS
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Alector (ALEC), ProKidney (PROK), Voyager Therapeutics (VYGR), Valneva (VALN), C4 Therapeutics (CCCC), Editas Medicine (EDIT), Taysha Gene Therapies (TSHA), Adaptive Biotechnologies (ADPT), Humacyte (HUMA), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.
85.8% of Alector shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 14.0% of Alector shares are held by company insiders. Comparatively, 24.3% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Alector presently has a consensus price target of $14.00, suggesting a potential upside of 148.23%. Allogene Therapeutics has a consensus price target of $12.09, suggesting a potential upside of 305.56%. Given Alector's stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Alector.
Alector has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
In the previous week, Allogene Therapeutics had 10 more articles in the media than Alector. MarketBeat recorded 24 mentions for Allogene Therapeutics and 14 mentions for Alector. Allogene Therapeutics' average media sentiment score of 0.50 beat Alector's score of 0.48 indicating that Alector is being referred to more favorably in the media.
Allogene Therapeutics received 122 more outperform votes than Alector when rated by MarketBeat users. Likewise, 64.58% of users gave Allogene Therapeutics an outperform vote while only 60.58% of users gave Alector an outperform vote.
Alector has higher revenue and earnings than Allogene Therapeutics. Alector is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alector has a net margin of -125.11% compared to Alector's net margin of -223,139.98%. Alector's return on equity of -48.33% beat Allogene Therapeutics' return on equity.
Summary
Allogene Therapeutics beats Alector on 11 of the 18 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
